menu
    • menu

    Find Olaparib manufacturers, exporters & distributors on PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Olaparib

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Olaparib

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    48

    API Suppliers

    API Suppliers

    16

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    5

    EU WC

    EU WC

    6

    KDMF

    KDMF

    13

    NDC API

    NDC API

    0

    VMF

    NDC API

    27

    Listed Suppliers

    Other Suppliers

    39INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    13

    Others

    FINISHED DOSAGE FORMULATIONS

    45

    FDF Dossiers

    FDF Dossiers

    5

    FDA Orange Book

    FDA (Orange Book)

    7

    Europe

    Europe

    2

    Canada

    Canada

    22

    Australia

    Australia

    2

    South Africa

    South Africa

    7

    Listed Dossiers

    Listed Dossiers

    317DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    111RELATED EXCIPIENT COMPANIES

    216EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    117

    US Patents

    10

    US Exclusivities

    16

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 7,247

    GLOBAL SALES INFORMATION

    US Medicaid

    487,431,793

    Annual Reports

    20,976

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    9

    API

    5

    FDF

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    276

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281
    Molecular Formula
    C24H23FN4O3
    Molecular Weight
    434.5  g/mol
    InChI Key
    FDLYAMZZIXQODN-UHFFFAOYSA-N
    FDA UNII
    WOH1JD9AR8
    Olaparib
    Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
    Olaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.
    1 2D Structure

    Olaparib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
    2.1.2 InChI
    InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
    2.1.3 InChI Key
    FDLYAMZZIXQODN-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
    2.2 Other Identifiers
    2.2.1 UNII
    WOH1JD9AR8
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Azd 2281

    2. Azd-2281

    3. Azd221

    4. Azd2281

    5. Lynparza

    2.3.2 Depositor-Supplied Synonyms

    1. 763113-22-0

    2. Lynparza

    3. Azd2281

    4. Azd-2281

    5. Ku-0059436

    6. Azd 2281

    7. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine

    8. Olaparib (azd-2281)

    9. 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

    10. Ku-59436

    11. Olaparib (azd2281, Ku-0059436)

    12. 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2h-phthalazin-1-one

    13. Az2281

    14. Mfcd13185161

    15. Woh1jd9ar8

    16. Nsc-747856

    17. C24h23fn4o3

    18. Chebi:83766

    19. 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2h)-one

    20. 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one

    21. Az-2281

    22. Keylynk-010 Component Olaparib

    23. Ku59436

    24. Olaparib Component Of Keylynk-010

    25. Olaparib [inn]

    26. Olaparib Cpd

    27. Olaparib (azd2281; Ku-0059436)

    28. Olaparib [usan:inn]

    29. Unii-woh1jd9ar8

    30. Olaparib (azd2281)

    31. Acylpiperazine Analogue, 47

    32. Olaparibum

    33. Azd221

    34. 4-[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2h)-one

    35. Olaparib- Bio-x

    36. Lynparza (tn)

    37. 09l

    38. 4-((3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorophenyl)methyl)phthalazin-1(2h)-one

    39. 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2h)-one

    40. 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2h)-one

    41. Ku 59436

    42. Olaparib [usan]

    43. Olaparib [jan]

    44. Ku0059436

    45. Olaparib [mi]

    46. Olaparib [vandf]

    47. Olaparib - Azd2281

    48. Olaparib [mart.]

    49. Olaparib [who-dd]

    50. Azd-2281 (olaparib)

    51. Olaparib (jan/usan/inn)

    52. Mls006010185

    53. Schembl426568

    54. Olaparib [orange Book]

    55. Chembl521686

    56. Gtpl7519

    57. Bdbm27566

    58. Dtxsid60917988

    59. Ex-a002

    60. Bcpp000360

    61. Hms3295i09

    62. Hms3426c03

    63. Hms3654g13

    64. Hms3746k07

    65. Hms3870h03

    66. Amy10295

    67. Bcp01872

    68. 763113-22-0, Lynparza,

    69. Nsc747856

    70. Nsc753686

    71. S1060

    72. Zinc40430143

    73. Akos005145764

    74. Ac-7939

    75. Bcp9000363

    76. Ccg-264799

    77. Cs-0075

    78. Db09074

    79. Ex-7210

    80. Nsc 747856

    81. Nsc-753686

    82. Sb14617

    83. Ss-4573

    84. Azd2281,olaparib, Ku-0059436

    85. Ncgc00238451-01

    86. Ncgc00238451-02

    87. Ncgc00238451-08

    88. Ncgc00238451-09

    89. Ncgc00238451-11

    90. 4-[(3-{[4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2h)-one

    91. 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2h)-phthalazinone

    92. Bo164169

    93. Hy-10162

    94. Smr004701291

    95. Sy040527

    96. Olaparib(azd2281,kudosku-0059436)

    97. A9666

    98. Bb 0260909

    99. Ft-0651458

    100. Ku 0059436

    101. Sw218142-2

    102. Ec-000.2324

    103. D09730

    104. J-503540

    105. Q7083106

    106. Brd-k02113016-001-08-9

    107. Brd-k02113016-001-09-7

    108. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine

    109. 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

    110. (2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

    111. 1(2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

    112. 1021843-02-6

    113. 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one

    114. Piperazine, 1-(cyclopropylcarbonyl)-4-(5-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)-2-fluorobenzoyl)-

    2.4 Create Date
    2008-02-11
    3 Chemical and Physical Properties
    Molecular Weight 434.5 g/mol
    Molecular Formula C24H23FN4O3
    XLogP31.9
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count4
    Exact Mass434.17541877 g/mol
    Monoisotopic Mass434.17541877 g/mol
    Topological Polar Surface Area82.1 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity790
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of: - Ovarian cancer, in which the medication is intended for [a] the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy, or [b] for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib. - Breast cancer, in which the medication is intended for use in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib.

    FDA Label

    * Ovarian cancer :

    Lynparza is indicated as monotherapy for the:

    - maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

    - maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

    Lynparza in combination with bevacizumab is indicated for the:

    - maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5. 1).

    * Breast cancer :

    Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer . Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5. 1).

    Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

    * Adenocarcinoma of the pancreas:

    Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

    * Prostate cancer :

    Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

    Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum based chemotherapy.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    The effect of olaparib on cardiac repolarization was assessed in 119 patients following a single dose of 300 mg and in 109 patients following multiple dosing of 300 mg twice daily. No clinically relevant effect of olaparib on QT interval was observed.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Poly(ADP-ribose) Polymerase Inhibitors

    Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    OLAPARIB
    5.3.2 FDA UNII
    WOH1JD9AR8
    5.3.3 Pharmacological Classes
    Poly(ADP-Ribose) Polymerase Inhibitors [MoA]; Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
    5.4 ATC Code

    L01XK01

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XK - Poly (adp-ribose) polymerase (parp) inhibitors

    L01XK01 - Olaparib

    5.5 Absorption, Distribution and Excretion

    Absorption

    Following oral administration, the absorption of olaparib is very rapid and can reach a peak concentration ranging between 4.7 and 9.1 mcg/ml after 1-3 hours. The reported AUC of olaparib after a dose of 200 mg is of 25.8 mcg.h/L and this AUC can be increased by 26% with constant administration. The consumption of a high-fat diet with olaparib can only decrease the tmax but do not have an effect in the peak concentration.

    Route of Elimination

    From the administered dose, approximately 86% of the administered dose is recovered after 7 days from which 44% is found in the urine and 42% is obtained in feces.

    Volume of Distribution

    After administration of a dose of 100 mg/kg, the reported volume of distribution was of 40.3 L.

    Clearance

    The total clearance of olaparib was reported to be 4.6 L/h.

    5.6 Metabolism/Metabolites

    Olaparib is extensively metabolized in the liver by the action of CYP3A isoenzymes. From the administered dose, the unchanged form of olaparib accounted for 70% of the circulating dose and it was considered the major component in urine and feces. The metabolic pathway of olaparib is mainly attributable to oxidation reactions with subsequent glucuronide and sulfate conjugation. However, the over 20 metabolites found in plasma, urine, and feces represented a minor portion of the administered dose. The major circulating metabolites were represented by the mono-oxygenated form and the piperazin-3-ol form.

    5.7 Biological Half-Life

    The reported elimination half-life ranges between 5 to 11 hours.

    5.8 Mechanism of Action

    Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

    API SUPPLIERS

    read-more
    read-more

    01

    Dr. Reddy's Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #9.1B48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2022-04-19

    Pay. Date : 2022-03-31

    DMF Number : 35742

    Submission : 2021-03-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2022-07-28

    Valid Till : 2025-12-30

    Written Confirmation Number : WC-0390

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 71796-034

    Start Marketing Date : 2021-11-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Kinsy SL

    Spain

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Biospain
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothReliable Spanish CDMO Delivering High-Quality APIs and Intermediates with Excellence, Flexibility, and Regulatory Compliance.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF ASMF arrow-down
    ✖
    Available Reg Filing : ASMF
    AUDIT
    Kinsy SL Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Axplora

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PREP
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAxplora is your partner of choice for complex APIs.

    Contact Supplier Contact Supplier
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Axplora CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Biophore India Pharmaceuticals Pvt...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #9.1A6
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40467

    Submission : 2024-09-28

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Biophore

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    LGM Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ChemOutsourcing
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Rochem International Inc

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #12.0F117
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Rochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Emay Pharmaceuticals

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEmay Pharmaceuticals is a GMP-certified API manufacturing company.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Emay Pharmaceuticals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Aarti Pharmalabs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Aarti Industries Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Jinan Tantu Chemicals

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Shanghai Minbiotech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641925800,"product":"OLAPARIB (TAX INVOICE NO:1905215340 DATE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"MASUNG COLTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"50000","totalValueFC":"7289.2","currency":"USD","unitRateINR":3620000,"date":"12-Jan-2022","totalValueINR":"543000","totalValueInUsd":"7289.2","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"7440417","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1650393000,"product":"OLAPARIB (TAX INVOICE NO:1905225009 DATE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"MASUNG COLTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"50000","totalValueFC":"7342.7","currency":"USD","unitRateINR":3693333.3333333335,"date":"20-Apr-2022","totalValueINR":"554000","totalValueInUsd":"7342.7","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"9831216","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653676200,"product":"OLAPARIB (TAX INV NO: 1905225045 DT:16.0","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"UNDISCLOSED","customerCountry":"BANGLADESH","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"12000","totalValueFC":"11890.9","currency":"USD","unitRateINR":919000,"date":"28-May-2022","totalValueINR":"919000","totalValueInUsd":"11890.9","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"1724938","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657132200,"product":"OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"12000","totalValueFC":"3433.2","currency":"USD","unitRateINR":910000,"date":"07-Jul-2022","totalValueINR":"273000","totalValueInUsd":"3433.2","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"2676561","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662057000,"product":"MSN PHARMACEUTICAL PRODUCT NAME OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.60","actualQuantity":"0.6","unit":"KGS","unitRateFc":"12000","totalValueFC":"7000.2","currency":"USD","unitRateINR":935000,"date":"02-Sep-2022","totalValueINR":"561000","totalValueInUsd":"7000.2","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"3912009","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO.ON0050721 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB HOT MELT EXTRUDES- BATCH NO.024","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO SUNDIA","customerCountry":"UNITED STATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"2350.8","totalValueFC":"1123","currency":"USD","unitRateINR":180000,"date":"08-Sep-2022","totalValueINR":"90000","totalValueInUsd":"1123","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669660200,"product":"OLAPARIB PREMIX IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"UNDISCLOSED","customerCountry":"RUSSIA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"2500","totalValueFC":"27385.5","currency":"USD","unitRateINR":186250,"date":"29-Nov-2022","totalValueINR":"2235000","totalValueInUsd":"27385.5","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5806511","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670005800,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"16.00","actualQuantity":"16","unit":"KGS","unitRateFc":"13000","totalValueFC":"200628","currency":"USD","unitRateINR":1033312.5,"date":"03-Dec-2022","totalValueINR":"16533000","totalValueInUsd":"200628","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5906138","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670524200,"product":"OLAPARIB DCG 25% W\/W (OTHER) (LUT (ARN)","address":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES","city":"MUMBAI,MAHARASHTRA","supplier":"BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SINGAPORE","customer":"ALCAPTLT","customerCountry":"SINGAPORE","quantity":"0.70","actualQuantity":"700","unit":"GMS","unitRateFc":"4.9","totalValueFC":"3385.7","currency":"EURO","unitRateINR":398.57142857142856,"date":"09-Dec-2022","totalValueINR":"279000","totalValueInUsd":"3385.7","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"6032492","productDescription":"API","marketType":"","country":"SINGAPORE","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677522600,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"0.29","actualQuantity":"0.29","unit":"KGS","unitRateFc":"7000","totalValueFC":"1913.1","currency":"USD","unitRateINR":544827.58620689658,"date":"28-Feb-2023","totalValueINR":"158000","totalValueInUsd":"1913.1","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"8131098","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678905000,"product":"OLAPARIB API","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO LLC","customerCountry":"UNITED STATES","quantity":"79.00","actualQuantity":"79","unit":"KGS","unitRateFc":"6626.7","totalValueFC":"520327.4","currency":"USD","unitRateINR":541735.69620253169,"date":"16-Mar-2023","totalValueINR":"42797120","totalValueInUsd":"520327.4","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29337990","bill_no":"4001590","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad-ZIPL-SEZ","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1687372200,"product":"OLAPARIB, B.NO. 2304003868, MFG.DT. MAY-","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"15000","totalValueFC":"4452.8","currency":"USD","unitRateINR":1219998.78,"date":"22-Jun-2023","totalValueINR":"365999.634","totalValueInUsd":"4452.8","indian_port":"BOMBAY AIR","hs_no":"29331999","bill_no":"0","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689877800,"product":"OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"10000","totalValueFC":"29517.1","currency":"USD","unitRateINR":808666.67700000003,"date":"21-Jul-2023","totalValueINR":"2426000.031","totalValueInUsd":"29517.1","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691951400,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"LOTUS PHARMACEUTICAL CO LTD","customerCountry":"TAIWAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"8121.1","totalValueFC":"40146.5","currency":"USD","unitRateINR":665116.80000000005,"date":"14-Aug-2023","totalValueINR":"3325584","totalValueInUsd":"40146.5","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000512","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692642600,"product":"OLAPARIB IH","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,","city":"HYDERABAD,TELANGANA","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"8428.9","totalValueFC":"16728.3","currency":"USD","unitRateINR":692855,"date":"22-Aug-2023","totalValueINR":"1385710","totalValueInUsd":"16728.3","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000523","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693247400,"product":"OLAPARIB - BATCH NO. OLP-23001, MANUFACTURING DT.","address":"S-553 GREATER KAILASH-II","city":"NEW DELHI","supplier":"SAI PHYTOCEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"CARPE SCHEIDER Y CIA S A","customerCountry":"ARGENTINA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"10.5","totalValueFC":"1036.1","currency":"USD","unitRateINR":858.28308000000004,"date":"29-Aug-2023","totalValueINR":"85828.308","totalValueInUsd":"1036.1","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"S-553 GREATER KAILASH-II, NEW DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697653800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (API) OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"7.20","actualQuantity":"7.2","unit":"KGS","unitRateFc":"9000","totalValueFC":"63859.7","currency":"USD","unitRateINR":738194.44444444438,"date":"19-Oct-2023","totalValueINR":"5315000","totalValueInUsd":"63859.7","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"4760317","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706553000,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BIOPROFARMA BAGO S A","customerCountry":"ARGENTINA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"21000","totalValueFC":"5993.8","currency":"USD","unitRateINR":1660516.6666666667,"date":"30-Jan-2024","totalValueINR":"498155","totalValueInUsd":"5993.8","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"7118633","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707762600,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TUTEUR SACIFIA","customerCountry":"ARGENTINA","quantity":"19.18","actualQuantity":"19.18","unit":"KGS","unitRateFc":"11000","totalValueFC":"207627.9","currency":"USD","unitRateINR":898210.16684045887,"date":"13-Feb-2024","totalValueINR":"17227671","totalValueInUsd":"207627.9","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"7489171","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710873000,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)(PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"LISBON","customer":"UNDISCLOSED","customerCountry":"PORTUGAL","quantity":"1.20","actualQuantity":"1.2","unit":"KGS","unitRateFc":"8000","totalValueFC":"9277","currency":"USD","unitRateINR":641939.05000000005,"date":"20-Mar-2024","totalValueINR":"770326.86","totalValueInUsd":"9277","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"8468505","productDescription":"API","marketType":"REGULATED MARKET","country":"PORTUGAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716575400,"product":"OLAPARIB IH (GST TAX INV.SI3624200796 DT: 30.04.2024)","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"5359.7","currency":"EURO","unitRateINR":893500,"date":"25-May-2024","totalValueINR":"446750","totalValueInUsd":"5359.7","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"1152722","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717353000,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"9000","totalValueFC":"265329.8","currency":"USD","unitRateINR":738319.40000000002,"date":"03-Jun-2024","totalValueINR":"22149582","totalValueInUsd":"265329.8","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"1389474","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726770600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS ? (API) (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT NAME ? OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"LISBON","customer":"UNDISCLOSED","customerCountry":"PORTUGAL","quantity":"5.50","actualQuantity":"5.5","unit":"KGS","unitRateFc":"8000","totalValueFC":"43268.4","currency":"USD","unitRateINR":659263.30545454554,"date":"20-Sep-2024","totalValueINR":"3625948.18","totalValueInUsd":"43268.4","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"4185472","productDescription":"API","marketType":"REGULATED MARKET","country":"PORTUGAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733077800,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GLOBAL PROJECT CELIK SANAYU DIS TI","customerCountry":"TURKEY","quantity":"9.40","actualQuantity":"9.4","unit":"KGS","unitRateFc":"9105.9","totalValueFC":"84216.3","currency":"USD","unitRateINR":761252.08404255309,"date":"02-Dec-2024","totalValueINR":"7155769.59","totalValueInUsd":"84216.3","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"6112943","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734978600,"product":"ACTIVE PHARMA INGREDIENTS (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT NAME - OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"UNDISCLOSED","customerCountry":"KOREA, REPUBLIC OF","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"9500","totalValueFC":"46831.5","currency":"USD","unitRateINR":795844.54000000004,"date":"24-Dec-2024","totalValueINR":"3979222.7","totalValueInUsd":"46831.5","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"6711693","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738521000,"product":"OLAPARIB (FINE CHEMICALS) (INV NO. PEX\/1187\/24-25 DT: 17.01.2025)","address":"2ND FLOOR, GODOWN No. 204","city":"MUMBAI","supplier":"AARTI PHARMALABS LTD","supplierCountry":"INDIA","foreign_port":"WINNIPEG","customer":"TO ORDER","customerCountry":"CANADA","quantity":"61.01","actualQuantity":"61.01","unit":"KGS","unitRateFc":"2940","totalValueFC":"175438.8","currency":"USD","unitRateINR":250071.7384035404,"date":"03-Feb-2025","totalValueINR":"15256876.76","totalValueInUsd":"175438.8","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"7851987","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2ND FLOOR, GODOWN No. 204, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1739298600,"product":"(REWARD ITEM)(PHARMACEUTICAL ALLOPATHICRAW MATERIALOF PHARMACEUTICAL GRADE) OLAPARIB(TAX INV.VLS\/EXP\/32\/2024-25)","address":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA","city":"N\/A","supplier":"VANNSH LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"PHARMA LORD PVT LTD","customerCountry":"PAKISTAN","quantity":"0.08","actualQuantity":"75","unit":"GMS","unitRateFc":"30","totalValueFC":"2183.5","currency":"USD","unitRateINR":2531.8464000000004,"date":"12-Feb-2025","totalValueINR":"189888.48","totalValueInUsd":"2183.5","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"8096709","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA, N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1739471400,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"4920.3","totalValueFC":"73581","currency":"USD","unitRateINR":426593.478,"date":"14-Feb-2025","totalValueINR":"6398902.17","totalValueInUsd":"73581","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"8171056","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745865000,"product":"OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BAGDAD, METROPOLITAN","customer":"SAMA ALFAYHAA PHARMACEUTICAL INDUST","customerCountry":"IRAQ","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"7500","totalValueFC":"7267.3","currency":"USD","unitRateINR":622096,"date":"29-Apr-2025","totalValueINR":"622096","totalValueInUsd":"7267.3","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"1387866","productDescription":"API","marketType":"","country":"IRAQ","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1747593000,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TUTEUR S A C I F I A","customerCountry":"ARGENTINA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"8075","totalValueFC":"238783.3","currency":"USD","unitRateINR":678149.65000000002,"date":"19-May-2025","totalValueINR":"20344489.5","totalValueInUsd":"238783.3","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"1955188","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748370600,"product":"OLAPARIB (FORM-A) IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"MICROSULE ARGENTINA S.A.","customerCountry":"ARGENTINA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"9200","totalValueFC":"8991.4","currency":"USD","unitRateINR":766072,"date":"28-May-2025","totalValueINR":"766072","totalValueInUsd":"8991.4","indian_port":"Hyderabad Air","hs_no":"29334990","bill_no":"2211362","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748889000,"product":"OLAPARIB BATCH NO:OLBD24001","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX INDIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"M\/S KRKA D.D NOVO MESTO","customerCountry":"SLOVENIA","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"5.5","totalValueFC":"1012","currency":"USD","unitRateINR":434.79050000000001,"date":"03-Jun-2025","totalValueINR":"86958.1","totalValueInUsd":"1012","indian_port":"Bangalore Air","hs_no":"29335990","bill_no":"2393125","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1749493800,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"21.00","actualQuantity":"21","unit":"KGS","unitRateFc":"3093.8","totalValueFC":"64307.9","currency":"USD","unitRateINR":263127.69,"date":"10-Jun-2025","totalValueINR":"5525681.49","totalValueInUsd":"64307.9","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"2583959","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1750876200,"product":"OLAPARIB (FORM-A)","address":"HETERO CORPORATE, NO. 7-2-A2,,INDU","city":"HYDERABAD,TELANGANA","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"APIIC MAHABOOBNAGAR","customer":"HETERO LABS LTD SEZ UNIT I","customerCountry":"INDIA","quantity":"110.00","actualQuantity":"110","unit":"KGS","unitRateFc":"2629","totalValueFC":"289277.4","currency":"USD","unitRateINR":225966.17554545452,"date":"26-Jun-2025","totalValueINR":"24856279.31","totalValueInUsd":"289277.4","indian_port":"SEZ\/Mahaboobnagar","hs_no":"29334900","bill_no":"3049118","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"SEZ\/Mahaboobnagar","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,,INDU, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1751999400,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"3093.8","totalValueFC":"91125.3","currency":"USD","unitRateINR":261426.10000000001,"date":"09-Jul-2025","totalValueINR":"7842783","totalValueInUsd":"91125.3","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"3407201","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1752431400,"product":"OLAPARIB","address":"A-2,419, CELEBRATION CITY CENTER,,","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"APRAMEYA PHARMACHEM FZCO","customerCountry":"UNITED ARAB EMIRATES","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"3027.6","totalValueFC":"29725.5","currency":"USD","unitRateINR":255835.57999999999,"date":"14-Jul-2025","totalValueINR":"2558355.8","totalValueInUsd":"29725.5","indian_port":"Bombay Air","hs_no":"29337990","bill_no":"3546039","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,,, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1666981800,"product":"LUT-65 OLAPARIB (BATCH 22003LR34S AND 22002IR34S)(17 DRUMS ON 02 PALLETS)","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"NA","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"64.13","actualQuantity":"64.125","unit":"KGS","unitRateFc":"7200","totalValueFC":"470766.3","currency":"USD","unitRateINR":"604080","date":"29-Oct-2022","totalValueINR":"38736630","totalValueInUsd":"470766.3","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"3080302","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669055400,"product":"OLAPARIB (TEST LIC.NO. TL\/AZ\/22\/002729) FOR R & D PURPOSE NOT FOR SALE (FOC)","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"BIO DURO SUNDIA","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"ZYDUS LIFESCIENCES LTD","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"409.1","currency":"USD","unitRateINR":"667674.6","date":"22-Nov-2022","totalValueINR":"33383.73","totalValueInUsd":"409.1","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"3422337","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705948200,"product":"LUT-65 OLAPARIB FORMA A (CAS763113-22-0 IUPAC4-(3-(4-(CYCLOPROPANECARBONYL)PIPERAZINE-1-CARBONYL)-4-FLOROPHENYL)METHY","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"OLON S P A","supplierCountry":"ITALY","foreign_port":"MILAN - MALPENSA","customer":"SANDOZ PRIVATE LTD","customerCountry":"INDIA","quantity":"23.73","actualQuantity":"23.73","unit":"KGS","unitRateFc":"6600","totalValueFC":"158480.4","currency":"USD","unitRateINR":"555060","date":"23-Jan-2024","totalValueINR":"13171573.8","totalValueInUsd":"158480.4","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"9785375","productDescription":"API","marketType":"REGULATED MARKET","country":"ITALY","selfForZScoreResived":"Pharma Grade","supplierPort":"MILAN - MALPENSA","supplierAddress":"STR. RIVOLTANA KM 6\/720053 RODANO MI ITSDNF ITALY","customerAddress":"SANDOZ HOUSE"}]
    12-Jan-2022
    14-Jul-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pathos AI Raises $365M Series D to Boost Oncology Drug Discovery via AI

    Details:

    The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.


    Lead Product(s): Pocenbrodib,Abiraterone Acetate,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

    Sponsor: Undisclosed

    Deal Size: $365.0 million Upfront Cash: Undisclosed

    Deal Type: Series D Financing May 15, 2025

    blank

    01

    Pathos

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Pathos

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pocenbrodib,Abiraterone Acetate,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : $365.0 million

    Deal Type : Series D Financing

    DEALS_DEV arrow-down

    Pathos AI Raises $365M Series D to Boost Oncology Drug Discovery via AI

    Details : The proceeds will support advancement of the company’s clinical-stage pipeline, which includes FT-7051 (pocenbrodib) is being evaluated for metastatic castration-resistant prostate cancer.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    May 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Details:

    Undisclosed


    Lead Product(s): Sacituzumab Tirumotecan,Pembrolizumab,Carboplatin,Paclitaxel,Doxorubicin Hydrochloride,Epirubicin Hydrochloride,Cyclophosphamide,Capecitabine,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody-drug Conjugate

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 13, 2025

    blank

    02

    Merck & Co

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Sacituzumab Tirumotecan,Pembrolizumab,Carboplatin,Paclitaxel,Doxorubicin Hydrochloride,Epirubicin Hydrochloride,Cyclophosphamide,Capecitabine,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-28...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    May 13, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patie...

    Details:

    Undisclosed


    Lead Product(s): IMNN-001,Paclitaxel,Carboplatin,Olaparib,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Cell and Gene therapy

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 07, 2025

    blank

    03

    Imunon

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Imunon

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : IMNN-001,Paclitaxel,Carboplatin,Olaparib,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    April 07, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Details:

    Undisclosed


    Lead Product(s): FPI-2265,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Radiolabeled Compounds

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 04, 2025

    blank

    04

    Fusion Pharma

    Canada
    arrow
    ChemOutsourcing
    Not Confirmed

    Fusion Pharma

    Canada
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : FPI-2265,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate ...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Radiolabeled Compounds

    Upfront Cash : Inapplicable

    April 04, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

    Details:

    Undisclosed


    Lead Product(s): Pembrolizumab,Paclitaxel,Carboplatin,Doxorubicin Hydrochloride,Boserolimab,Epirubicin Hydrochloride,Cyclophosphamide,Capecitabine,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 17, 2025

    blank

    05

    Merck & Co

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pembrolizumab,Paclitaxel,Carboplatin,Doxorubicin Hydrochloride,Boserolimab,Epirubicin Hydrochloride,Cyclophosphamide,Capecitabine,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Antibody

    Upfront Cash : Inapplicable

    February 17, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment i...

    Details:

    Undisclosed


    Lead Product(s): Durvalumab,Carboplatin,Paclitaxel,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Apices Soluciones

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 24, 2024

    blank

    06

    AstraZeneca

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Durvalumab,Carboplatin,Paclitaxel,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Apices Soluciones

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Antibody

    Upfront Cash : Inapplicable

    December 24, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    LYNPARZA® Shows Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

    Details:

    Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of BRCA-mutated HER2-negative high-risk early breast cancer.


    Lead Product(s): Olaparib,Inapplicable

    Therapeutic Area: Oncology Brand Name: Lynparza

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 11, 2024

    blank

    07

    AstraZeneca

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    LYNPARZA® Shows Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial

    Details : Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of BRCA-mutated HER2-negative high-risk early breast cancer.

    Product Name : Lynparza

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 11, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer

    Details:

    Undisclosed


    Lead Product(s): Olaparib,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: AstraZeneca

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 02, 2024

    blank

    08

    Gustave Roussy

    Country
    arrow
    ChemOutsourcing
    Not Confirmed

    Gustave Roussy

    Country
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemorad...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 02, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    AstraZeneca Pharma Gets nod for Sale, Distribution of Cancer Drug Lynparza

    Details:

    Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of advanced or recurrent endometrial cancer in adults.


    Lead Product(s): Olaparib,Durvalumab

    Therapeutic Area: Oncology Brand Name: Lynparza

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 27, 2024

    blank

    09

    AstraZeneca

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib,Durvalumab

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    AstraZeneca Pharma Gets nod for Sale, Distribution of Cancer Drug Lynparza

    Details : Lynparza (olaparib) is a PARP 1/2/3 inhibitor small molecule drug candidate which is indicated for the treatment of advanced or recurrent endometrial cancer in adults.

    Product Name : Lynparza

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 27, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic

    Details:

    The funds will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, to treat human cancers.


    Lead Product(s): EIS-12656,Olaparib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule

    Sponsor: CPRIT

    Deal Size: $4.7 million Upfront Cash: Undisclosed

    Deal Type: Funding November 26, 2024

    blank

    10

    Eisbach Bio

    Denmark
    arrow
    ChemOutsourcing
    Not Confirmed

    Eisbach Bio

    Denmark
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : EIS-12656,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : CPRIT

    Deal Size : $4.7 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic

    Details : The funds will support the clinical development of Eisbach's first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1, to treat human cancers.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    November 26, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    INTERMEDIATE SUPPLIERS

    read-more
    read-more

    01

    Allchem Lifescience

    India
    CAMX
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    N-Boc-Piperazine

    CAS Number : 57260-71-6

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Allchem Lifescience

    India
    CAMX
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropane carboxylic acid

    CAS Number : 1759-53-1

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Allchem Lifescience

    India
    CAMX
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropyl Carbonyl Chloride

    CAS Number : 4023-34-1

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Allchem Lifescience

    India
    CAMX
    Not Confirmed
    arrow

    Allchem Lifescience

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    1-Cyclopropyl carbonyl piperazine

    CAS Number : 59878-57-8

    End Use API : Olaparib

    About The Company : Established in 2003 with small pilot plant and came in to commercial production in 2013 in the name of Allchem Laboratories, it is an independent privately owne...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2-FLUORO-5-FORMYL BENZONITRILE

    CAS Number : 218301-22-5

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    2-FLUORO-5-((4-OXO-3,4-DIHYDROPHTHALAZIN-1-YL) ME...

    CAS Number : 763114-26-7

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    DIMETHYL (3-OXO-1,3-DIHYDRO-2-BENZOFURAN-1-YL) PH...

    CAS Number : 61260-15-9

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CYCLOPROPANECARBONYL CHLORIDE

    CAS Number : 4023-34-1

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow

    Ami Organics Private Limited

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CYCLOPROPYL CARBONYL PIPERAZINE

    CAS Number : 59878-57-8

    End Use API : Olaparib

    About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Inventys

    India
    CAMX
    Not Confirmed
    arrow

    Inventys

    India
    CAMX
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cyclopropane Carboxylic Acid

    CAS Number : 1759-53-1

    End Use API : Olaparib

    About The Company : INVENTYS Research Company – India’s Leading CDMO of Actives, Advanced Intermediates, and Specialty Chemicals. A research-driven Exclusive Synthesis and CDMO...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Topical

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 763113-22-0 / Olaparib API manufacturers, exporters & distributors?

    Olaparib manufacturers, exporters & distributors 1

    78

    PharmaCompass offers a list of Olaparib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olaparib manufacturer or Olaparib supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olaparib manufacturer or Olaparib supplier.

    PharmaCompass also assists you with knowing the Olaparib API Price utilized in the formulation of products. Olaparib API Price is not always fixed or binding as the Olaparib Price is obtained through a variety of data sources. The Olaparib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Olaparib

    Synonyms

    763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281

    Cas Number

    763113-22-0

    Unique Ingredient Identifier (UNII)

    WOH1JD9AR8

    About Olaparib

    Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Manufacturers

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one, including repackagers and relabelers. The FDA regulates 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Suppliers

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one supplier is an individual or a company that provides 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one active pharmaceutical ingredient (API) or 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one finished formulations upon request. The 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers may include 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one API manufacturers, exporters, distributors and traders.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USDMF

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one DMF (Drug Master File) is a document detailing the whole manufacturing process of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one active pharmaceutical ingredient (API) in detail. Different forms of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one DMFs exist exist since differing nations have different regulations, such as 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one DMF submitted to regulatory agencies in the US is known as a USDMF. 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USDMF includes data on 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with USDMF on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Drug Master File in Korea (4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one. The MFDS reviews the 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF as part of the drug registration process and uses the information provided in the 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF to evaluate the safety and efficacy of the drug.

    After submitting a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with KDMF on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one WC

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one written confirmation (4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one WC) is an official document issued by a regulatory agency to a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one manufacturer, verifying that the manufacturing facility of a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one APIs or 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one finished pharmaceutical products to another nation, regulatory agencies frequently require a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one WC (written confirmation) as part of the regulatory process.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with Written Confirmation (WC) on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one suppliers with NDC on PharmaCompass.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one GMP

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one GMP manufacturer or 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one GMP API supplier for your needs.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one CoA

    A 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one CoA (Certificate of Analysis) is a formal document that attests to 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one's compliance with 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one specifications and serves as a tool for batch-level quality control.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one CoA mostly includes findings from lab analyses of a specific batch. For each 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one may be tested according to a variety of international standards, such as European Pharmacopoeia (4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one EP), 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one JP (Japanese Pharmacopeia) and the US Pharmacopoeia (4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search